Amersham logo'Leadership through innovation' - Interim Report & Accounts 2003
Leadership through innovationReport homepageMain website
Highlights from the first half Next page
Previous page
 


The business performance and statutory results are summarised below. The commentary and tables in this Interim Report are on a business performance basis unless otherwise stated. Business performance results are stated before exceptional items and goodwill amortisation unless otherwise noted. Management believes that exclusion of these items provides a better comparison of business performance for the periods presented. All growth rates are stated at constant exchange (CER) unless otherwise noted.

Business performance
 
6 months
to 30 Jun 03
£m
  6 months
to 30 Jun 03
£m
  Growth at constant
exchange rates
£m
 
Sales* 808   812   6 #
Operating profit 141   165   5  
Profit before tax 140   159   8  
EPS 13.7 p 15.5 p 7  
Dividend per share 1.85 p 2.65 p 8  

Sales up 6%# to £808 million, profit before tax up 8% at £140 million, earnings per share up 7% and dividend per share up 8%

Adverse impact of foreign exchange on first half profit before tax of £29 million

Growth in earnings per share at constant exchange rate expected to be 8-10% for full year

Statutory results
 
6 months
to 30 Jun 03
£m
  6 months
to 30 Jun 03
£m
  Growth at constant
exchange rates
£m
 
Sales* 808   812   0  
Operating profit 77   144   (47 )
EPS 6.4 p 14.9 p (57 )

Statutory results show growth at actual exchange rates after charging restructuring costs of £41 million (2002 – £nil) and after goodwill amortisation of £22 million (2002 – £15 million)

*Turnover including share of joint venture
#Denotes ongoing business growth excluding discontinued products

 
Investor tools:
Search this site
Print this page
Download PDF - Interim Report & Accounts 2003 [3.73 Mb]
Further information about the topics covered on this page can be found at:
Overview of Amersham plc
Overview of Amersham Health
Overview of Amersham Biosciences
Investors overview

Next page
Previous page

© Amersham plc - All rights reserved  Privacy policy - Terms & conditions - GE Healthcare